Loading
Old version — revision 1
This is a fixed snapshot of Geroscience hypothesis, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/geroscience-hypothesis.md — the filesystem corpus, unchanged. Not an edit.
The proposition that aging is the shared upstream driver of most chronic disease, so that slowing it would delay many conditions at once rather than one at a time.
Geroscience hypothesis is the proposition that biological aging is the principal upstream driver of most chronic disease, and that an intervention slowing aging would therefore delay cancer, cardiovascular disease, dementia, diabetes and frailty together. It reframes the target of medicine from individual pathologies to the process that makes all of them likely. The animal evidence for it is substantial. The human evidence is almost entirely absent.
Adult mortality risk rises roughly exponentially with age, doubling every seven to eight years, and the incidence curves for most chronic diseases follow it closely. Someone at seventy is not merely more likely to have cancer than someone at thirty; they are also more likely to have heart disease, dementia, kidney disease and osteoporosis, and to have several at once. The geroscience argument reads this covariance as evidence of a common cause.
The competing-risk arithmetic supplies the practical motivation. Because an older person who avoids one fatal disease usually dies of another, eliminating any single disease adds surprisingly little to population life expectancy. Removing all cancer deaths would add roughly three years at birth by standard estimates. An intervention that shifted the entire aging trajectory, by contrast, would push every curve to the right simultaneously.
Why the framing changes what gets fundedUnder the disease-by-disease model, a drug that reduced frailty, improved immune response to vaccination and delayed dementia by a modest amount in one trial would have no regulatory home. Under the geroscience framing, that combination is the point.
The intellectual precursors run through Gompertz's 1825 mortality law, through James Fries's 1980 argument for Compression of morbidity, and through the demonstration in the 1980s and 1990s that single-gene mutations could extend lifespan in nematodes and mice while delaying multiple age-related pathologies, of which the 1993 daf-2 result in nematodes is the best known.
The modern formulation dates to the early 2010s. A trans-NIH Geroscience Interest Group formed in 2012 and convened a summit the following year, and a 2014 paper by Brian Kennedy and colleagues set out seven "pillars of aging" as a shared conceptual base: adaptation to stress, epigenetics, inflammation, macromolecular damage, metabolism, proteostasis, and stem cells and regeneration.1 The pillars overlap heavily with the Hallmarks of aging and were framed more explicitly around translation, grouping mechanisms such as Proteostasis collapse failure, chronic inflammation and Stem cell exhaustion as shared substrates rather than as separate research areas. In parallel, S. Jay Olshansky and colleagues argued the economic case that became the The longevity dividend.2 Institutions built around the framing, notably the Buck Institute for Research on Aging, predate the label by more than a decade.
The strongest support comes from interventions that extend lifespan in mammals and delay multiple pathologies at once. Caloric restriction does this across many species. Rapamycin extends lifespan in genetically heterogeneous mice even when started late in life,3 and treated mice show delayed decline in immune and cognitive function. Growth-hormone-pathway mutants such as Ames dwarf and growth hormone receptor knockout mice live longer and develop tumours later. Senolytics improve function across several tissues in aged mice.
Crucially, these interventions do not act on one disease. A rapamycin-fed mouse is not protected against cancer alone; decline is delayed in several tissues at once, although not uniformly, and some age-related pathologies proceed unchanged. That multi-system pattern is what the hypothesis predicts, and it is why the animal literature is treated as strong evidence.
Human support is indirect. People who reach extreme old age tend to compress their period of illness rather than extend it, developing major disease later and dying after a shorter terminal decline than people who die in their seventies.4 Long-lived families show delayed onset across several unrelated conditions. Common variants associated with longevity are few and of small effect, but the familial clustering is real.
A revealing natural experiment is Laron syndrome, in which growth hormone receptor signalling is absent. An Ecuadorian cohort followed for decades showed near-absence of cancer and of type 2 diabetes, matching the mouse mutants, without a corresponding increase in lifespan; deaths came instead from accidents, alcohol-related causes and cardiovascular disease.5 The result supports the disease-delay half of the hypothesis and complicates the lifespan half.
What does not exist is a randomised human trial showing that any intervention slows aging. Exercise is the best-evidenced practice for delaying multiple age-related outcomes, and it is not a drug. Metformin and the TAME trial, NAD+ precursors and other candidates have not demonstrated the effect in controlled human studies.
The framework may be a taxonomy, not a theory. Listing pillars or hallmarks does not establish that they share a driver, and interventions that hit one hallmark do not reliably move the others. Clearing senescent cells does not repair mitochondrial damage; restoring autophagic flux does not lengthen telomeres. Critics argue that "aging" names a correlated bundle of processes rather than a single manipulable variable, and that the appeal of the framing outruns its explanatory content.
Mouse results translate badly. The mammalian aging literature has produced few candidates that survive contact with human trials. Senolytic drugs are the clearest current example: dramatic mouse data followed by human results that have been modest or null.
Trade-offs are underweighted. Rapamycin is an immunosuppressant at transplant doses. Growth-hormone pathway suppression costs stature and, in mice, some cognitive and wound-healing capacity. An intervention that slows aging by slowing everything may not be one people want.
Success might expand morbidity rather than compress it. The empirical record in high-income countries over recent decades is closer to expansion of the years lived with disease than to compression, which is a point against the optimistic reading of what delaying aging would deliver.
No major regulator recognises aging as an indication, so a drug cannot be approved to treat it. The exception is veterinary: the US Food and Drug Administration's animal-drug centre will consider lifespan extension itself as an indication, which is the route Loyal is taking in dogs, and nothing about that pathway carries over to human approval. The workaround pursued by Nir Barzilai and colleagues is TAME, designed less as a test of the drug itself than as a template: a trial whose primary endpoint is time to the first occurrence of any of several age-related diseases or death, which if accepted would establish that a multi-disease endpoint can support a label. It has never been fully funded, in part because a generic drug offers no sponsor a return, and it has not enrolled.
The alternative route is a validated surrogate. Without one, geroscience trials are long and expensive, which is the problem set out under Aging biomarkers. The field's difficulty is that its two paths to the clinic each depend on the other being easy.
A clean test would take a single intervention, apply it to a population in a randomised trial, and show delayed onset across several unrelated age-related conditions relative to placebo, with functional measures moving in the same direction. Nothing of that design has reported. Intermediate evidence may come from companion dogs, whose lifespans are short enough to observe and whose environment resembles their owners'; work of this kind has faced funding instability. Until such a result exists, geroscience remains a well-motivated hypothesis with a strong animal literature and no human demonstration, and claims about Longevity escape velocity or Maximum human lifespan that assume it has been proven are assuming the conclusion.
paperKennedy, B.K. et al. "Geroscience: linking aging to chronic disease." Cell, 2014. ↩
paperOlshansky, S.J., Perry, D., Miller, R.A., Butler, R.N. "In pursuit of the longevity dividend." The Scientist, 2006.↩An essay in a science magazine making an economic case for funding aging research, not an empirical study.
paperHarrison, D.E. et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature, 2009.↩Treatment began at 20 months of age, and the median lifespan gain was larger in females than in males.
paperAndersen, S.L. et al. "Health span approximates life span among many supercentenarians: compression of morbidity at the approximate limit of life span." The Journals of Gerontology: Series A, 2012.↩The subjects are people who already reached extreme age, a group selected on the outcome, so the pattern need not generalise.
paperGuevara-Aguirre, J. et al. "Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans." Science Translational Medicine, 2011. ↩